Edward Doo, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
5
0
4
N/A
0
8
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Averell Sherker, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Shared therapeutic areas:
Worked with same sponsors:
Marc G Ghany, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Shared therapeutic areas:
Worked with same sponsors:
Anna Lok, MD
University of Michigan
Shared therapeutic areas:
Worked with same sponsors:
General Manager
Tanabe Pharma Corporation
Shared therapeutic areas:
Yan Huang
Xiangya Hospital of Central South University
Shared therapeutic areas:
Ed Doo, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Shared therapeutic areas:
Worked with same sponsors:
Michael Roden, Prof., MD
German Diabetes Center
Shared therapeutic areas:
Stephen A. Harrison, MD
Brooke Army Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Salomé Pérez
University of Navarra
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Losartan for the Treatment of Pediatric NAFLD
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B
Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
All 5 trials loaded